ID | 118614 |
Author |
Kondo, Yoshihiro
National Hospital Organization Kochi Hospital
Kunishige, Michihiro
National Hospital Organization Kochi Hospital
Kadota, Naoki
National Hospital Organization Kochi Hospital
Okano, Yoshio
National Hospital Organization Kochi Hospital
Machida, Hisanori
National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo
National Hospital Organization Kochi Hospital
Naruse, Keishi
National Hospital Organization Kochi Hospital
Shinohara, Tsutomu
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Takeuchi, Eiji
National Hospital Organization Kochi Hospital
|
Keywords | durable response
immune-related hepatitis
non-small cell lung cancer
pembrolizumab
single dose
|
Content Type |
Journal Article
|
Description | Profound and durable responses to a single dose of pembrolizumab in lung cancer are rare. We encountered a non-small cell lung cancer patient showing a deep and durable response with a single dose of pembrolizumab. A 79-year-old man reported bloody sputum for several weeks and visited a general physician. A chest x-ray revealed a tumor shadow in the right middle lung field at that time, and the patient was referred to our hospital. He was diagnosed with adenocarcinoma of the lung by transbronchial biopsy. The expression of programmed death ligand 1 in tumor cells was 100% by immunostaining. Based on the above, immunotherapy with pembrolizumab was performed as first-line therapy. Cancer cells had significantly shrunk at the end of the first cycle. The patient had grade-3 immune-related hepatitis at the end of the first cycle. Pembrolizumab treatment was stopped and prednisolone (80 mg/body) was initiated. Subsequently, liver function normalized, and prednisolone was tapered and discontinued. Since then, no tumor recurrence has been detected for 1.5 years without treatment. There have been few reports of profound and durable responses to a single dose of pembrolizumab in lung cancer. The results indicate that a single dose of pembrolizumab alone may be sufficient to cause durable response and serious immune-related adverse events in some cases.
|
Journal Title |
Thoracic Cancer
|
ISSN | 17597714
17597706
|
Publisher | China Lung Oncology Group|John Wiley & Sons Australia
|
Volume | 13
|
Issue | 4
|
Start Page | 648
|
End Page | 652
|
Published Date | 2022-01-12
|
Rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|